23
Mar

A Break from COVID 19 – The Nitrosamine Saga Is Far from Over

Remember the days when the biggest concern that both consumers and the pharmaceutical industry had was about potential contamination of medications by nitrosamines? Just a few weeks ago, rumors were flying around fast and furiously among patient groups on social media, firms were issuing recalls of numerous medications, and regulators were involved in issuing policies […]

Read More
30
Oct

Michelle Ryder, new Principal Consultant in the Regulatory Practice at Lachman Consultant Services, Inc.

We are pleased to announce that Michelle Ryder has accepted the position of Principal Consultant in the Regulatory Practice at Lachman Consultants, effective October 28, 2019. Ms. Ryder is a seasoned Regulatory professional with more than 20 years of experience in the pharmaceutical industry.  She has provided strategic leadership and plans for ANDA, NDA, and […]

Read More